uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Suicide risk and antipsychotic side effects in schizophrenia: nested case-control study.
Karolinska Inst, Karolinska Univ Hosp, Dept Med, Ctr Pharmacoepidemiol CPE, SE-17176 Stockholm, Sweden.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Psychiatry, University Hospital.
Karolinska Inst, Karolinska Univ Hosp, Dept Med, Ctr Pharmacoepidemiol CPE, SE-17176 Stockholm, Sweden.; Golestan Univ Med Sci, Fac Med, Gorgan, Iran..
Karolinska Inst, Karolinska Univ Hosp, Dept Med, Ctr Pharmacoepidemiol CPE, SE-17176 Stockholm, Sweden.
Show others and affiliations
2016 (English)In: Human Psychopharmacology: Clinical and Experimental, ISSN 0885-6222, E-ISSN 1099-1077, Vol. 31, no 4, 341-345 p.Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: This study explores suicide risk in schizophrenia in relation to side effects from antipsychotic medication.

METHODS: Among patients with a first clinical discharge diagnosis of schizophrenia or schizoaffective disorder in Stockholm County between 1984 and 2000 (n = 4000), those who died by suicide within 5 years from diagnosis were defined as cases (n = 84; 54% male). For each case, one individually matched control was identified from the same population. Information on antipsychotic side effects, including extrapyramidal symptoms (EPS) and akathisia, as well as prescriptions of anticholinergic medication, was retrieved from clinical records in a blinded fashion. Adjusted odds ratios (aORs) with 95% confidence intervals (CIs) of the association between suicide and side effects as well as anticholinergic medication were estimated using conditional logistic regression.

RESULTS: A lower suicide risk was found in patients with a history of EPS (aOR 0.33, 95% CI 0.12-0.94). There was no statistically significant association between akathisia or anticholinergic medication use and the suicide risk.

CONCLUSIONS: A lower suicide risk identified among patients with EPS could potentially reflect higher antipsychotic adherence, exposure to higher dosage, or polypharmacy among these patients.

Place, publisher, year, edition, pages
2016. Vol. 31, no 4, 341-345 p.
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-288908DOI: 10.1002/hup.2536ISI: 000379939200010PubMedID: 27108775OAI: oai:DiVA.org:uu-288908DiVA: diva2:924421
Funder
Stockholm County CouncilSwedish Research Council, K2007-62X-15078-04-3, K2008-62P-20597-01-3
Available from: 2016-04-28 Created: 2016-04-28 Last updated: 2016-08-18Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Clapham, EricBodén, Robert
By organisation
Psychiatry, University Hospital
In the same journal
Human Psychopharmacology: Clinical and Experimental
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 92 hits
ReferencesLink to record
Permanent link

Direct link